Caspase 8 - Pipeline Review (H2 2018) Featuring BeyondSpring Pharmaceuticals, Conatus Pharmaceuticals and Novartis - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 20, 2018--The “Caspase 8 - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 184.108.40.206) - Caspase-8 is a caspase protein, encoded by the CASP8 gene. It binds to the adapter molecule FADD recruits it to either receptor. The resulting aggregate called death-inducing signaling complex (DISC) performs CASP8 proteolytic activation.ScopeThe report provides a snapshot of the global therapeutic landscape for Caspase 8The report reviews Caspase 8 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sourcesThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stagesThe report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activitiesThe report reviews key players involved in Caspase 8 targeted therapeutics and enlists all their major and minor projectsThe report assesses Caspase 8 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule typeThe report summarizes all the dormant and discontinued pipeline projectsThe report reviews latest news and deals related to Caspase 8 targeted therapeutics
Companies FeaturedBeyondSpring Pharmaceuticals Inc.Conatus Pharmaceuticals Inc.Novartis AG
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/trxpg3/caspase_8?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180920005376/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/20/2018 07:13 AM/DISC: 09/20/2018 07:13 AM